PP_1170x120_10-25-21

Osphena

Duchesnay Inc. receives approval for Osphena

Duchesnay Inc. receives approval for Osphena

BLAINVILLE, Quebec — Duchesnay Inc., a pharmaceutical company specializing in women’s health, announced today that the FDA has approved its supplemental New Drug Application (sNDA) seeking to add moderate to severe vaginal dryness, a symptom of vulvar and vaginal atrophy (VVA), due to menopause, to the indication of Osphena (ospemifene). The sNDA was based on new safety and

Duchesnay acquires Osphena U.S. rights from Shionogi

Duchesnay acquires Osphena U.S. rights from Shionogi

BLAINVILLE, Quebec, and OSAKA, Japan — Specialty pharmaceutical company Duchesnay has acquired exclusive U.S. and Canadian rights to market and distribute Osphena (ospemifene), a treatment for painful intercourse, from Shionogi Inc. The companies said the transaction gives Duchesnay the rights to develop, manufacture and commercialize ospemifene-based products in the United States and Canada. Duchesnay said